MEDIA INVITATION: The first European Vascular Genomics Network conference Media briefing
13 December 2004 - 13 December 2004
The media briefing, which will be held on the opening day of the EVGN conference (13-16 December) will highlight the research accomplishments of EVGN first year and its most recent and forthcoming scientific results. New state-of-the-art research results will be presented on: clinical perspectives in endothelial dysfunction; atherosclerotic plaque destabilization mechanisms and therapy; use of stem cells to treat coronary heart disease; vaccination against atherosclerosis; postgenomics approaches to cardiovascular disease.
Press representatives are invited to the media briefing. Participants will be available for interviews at the conference or via telephone.
WHO
-Andrew Newby,First EVGN Conference scientific coordinator, Bristol Heart Institute, Bristol Royal Infirmary, Bristol,- Alain Tedgui,EVGN coordinator, National Institute of Health and Medical Research (INSERM), Paris.,- Martin Bennett,Chancellors Master and Scholars of the University of Cambridge, Cambridge,- Stefanie Dimmeler,Molecular Cardiology, University of Frankfurt, Frankfurt,- Ingrid Fleming,Cardiovascular Physiology, University of Frankfurt, Frankfurt,- Göran Hansson,Center for Molecular Medicine, Karolinska Institute, Stockolm
More information on the EVGN are available at http://www.evgn.org/PRESS(opens in new window) CONTACTS,Ilaria Fazi,IFOM - The FIRC Institute of Molecular Oncology Foundation,Press Office and Communication,European Vascular Genomics Network - UE 6th Framework Programme: "Outreach to the general public",Tel. +39 02 56816055,Cell. +39 349 2305441,E-mail: ilaria.fazi@ifom-ieo-campus.it
Francesca Noceti,IFOM - The FIRC Institute of Molecular Oncology Foundation,Press Office and Communication Director,European Vascular Genomics Network - UE 6th Framework Programme: "Outreach to the general public",Tel. +39 02 574303206 - +39 02 5693063,Cell. +39 339 1779787,E-mail: team-press@ifom-ieo-campus.it
EVGN,The first annual EVGN Conference will mark the first year of the entry into force of the EVGN, the first ever European Union funded Network of Excellence in the field of cardiovascular disease, whose aim is promoting multidisciplinary interaction by uniting 25 basic and clinical institutions (encompassing 35 academic groups), 2 biotechnology companies and 1 management company, from 10 EU Member or Associated States.
Press representatives are invited to the media briefing. Participants will be available for interviews at the conference or via telephone.
WHO
-Andrew Newby,First EVGN Conference scientific coordinator, Bristol Heart Institute, Bristol Royal Infirmary, Bristol,- Alain Tedgui,EVGN coordinator, National Institute of Health and Medical Research (INSERM), Paris.,- Martin Bennett,Chancellors Master and Scholars of the University of Cambridge, Cambridge,- Stefanie Dimmeler,Molecular Cardiology, University of Frankfurt, Frankfurt,- Ingrid Fleming,Cardiovascular Physiology, University of Frankfurt, Frankfurt,- Göran Hansson,Center for Molecular Medicine, Karolinska Institute, Stockolm
More information on the EVGN are available at http://www.evgn.org/PRESS(opens in new window) CONTACTS,Ilaria Fazi,IFOM - The FIRC Institute of Molecular Oncology Foundation,Press Office and Communication,European Vascular Genomics Network - UE 6th Framework Programme: "Outreach to the general public",Tel. +39 02 56816055,Cell. +39 349 2305441,E-mail: ilaria.fazi@ifom-ieo-campus.it
Francesca Noceti,IFOM - The FIRC Institute of Molecular Oncology Foundation,Press Office and Communication Director,European Vascular Genomics Network - UE 6th Framework Programme: "Outreach to the general public",Tel. +39 02 574303206 - +39 02 5693063,Cell. +39 339 1779787,E-mail: team-press@ifom-ieo-campus.it
EVGN,The first annual EVGN Conference will mark the first year of the entry into force of the EVGN, the first ever European Union funded Network of Excellence in the field of cardiovascular disease, whose aim is promoting multidisciplinary interaction by uniting 25 basic and clinical institutions (encompassing 35 academic groups), 2 biotechnology companies and 1 management company, from 10 EU Member or Associated States.